Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 7, 2019

Primary Completion Date

March 4, 2021

Study Completion Date

June 14, 2021

Conditions
Immune Mediated Necrotizing Myopathy
Interventions
DRUG

zilucoplan

Daily subcutaneous (SC) inection

OTHER

Placebo

Daily subcutaneous (SC) inection

Trial Locations (18)

11021

Northwell Health Neuroscience Institute, Great Neck

19104

University of Pennsylvania, Philadelphia

20892

National Institute of Health, Bethesda

32209

University of Florida Health Jacksonville, Jacksonville

33612

University of South Florida, Tampa

38018

Wesley Neurology Clinic, Memphis

43221

The Ohio State University, Columbus

63110

Washington University School of Medicine in Saint Louis, St Louis

66160

University of Kansas Medical Center, Kansas City

75013

Hôpital Universitaire Pitié Salpêtrière, Paris

77030

The University of Texas Health Science Center at Houston, Houston

78756

Austin Neuromuscular Center, Austin

90095

University of California Los Angeles, Los Angeles

92868

University of California Irvine, Orange

02115

Brigham and Women's Hospital, Boston

1105 AZ

Amsterdam UMC, Amsterdam

WC1N3BG

University College London Hospitals NHS Foundation Trust, London

M6 8HD

Salford Royal NHS Barnes Clinical Research Facility, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ra Pharmaceuticals

INDUSTRY